Drugs / Larotinib
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05048368 | Oct → Dec 2026 expected | esophageal cancer | Sunshine Lake Pharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05057949 | Nov 2021 → Feb 2022 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05059743 | Nov 2021 → Jan 2022 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04131192 | Nov 2019 → Sep 2021 | malignant pancreatic neoplasm | Sunshine Lake Pharma Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03888092 | Aug 2017 → Dec 2022 | esophageal squamous cell carcinoma | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04415853 | Jan 2021 → Aug 2026 overdue | esophageal cancer | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Larotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05048368 ↗ |
| Known as | Lerotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04415853 ↗ |
| Known as | Z650 | “Single Dose \[14C\]-Larotinib（Z650）” NCT05059743 ↗ |
| Route | Oral | “Capsules, Oral” NCT05048368 ↗ |